Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Korea’s DxVx Plans Novel Cancer Vaccine In-licensing from its Partner Oxford Vacmedix

publication date: Nov 28, 2023

South Korea’s DxVx plans to in-license China and South Korea rights for a novel anti-cancer vaccine from Oxford Vacmedix (OVM), a spin-out from Oxford University. OVM-200 targets survivin, an apoptosis inhibitor that regulates cell division. The candidate uses OVM’s Recombinant Overlapping Peptide (ROP) technology to enhance immunity and vaccine efficacy. In Phase Ia tests, OVM-200 was safe and induced an immune response. DxVx, which owns 45% of OVM, plans to conduct Ib trials in China and South Korea that will be concurrent with OVM’s Ib trial. OVM and DxVx said negotiations on the in-licensing are at an advanced stage. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital